Russell Investments Group Ltd. Reduces Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Russell Investments Group Ltd. trimmed its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 31.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 100,496 shares of the company's stock after selling 46,650 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.16% of Dyne Therapeutics worth $1,337,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Dyne Therapeutics by 58.5% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,379 shares of the company's stock worth $75,000 after acquiring an additional 3,092 shares during the last quarter. Allspring Global Investments Holdings LLC increased its holdings in shares of Dyne Therapeutics by 95.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 9,310 shares of the company's stock valued at $83,000 after purchasing an additional 4,552 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in Dyne Therapeutics by 355.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 7,099 shares of the company's stock worth $94,000 after purchasing an additional 5,541 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in Dyne Therapeutics by 10.7% during the 3rd quarter. Principal Financial Group Inc. now owns 15,229 shares of the company's stock worth $136,000 after buying an additional 1,476 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in Dyne Therapeutics in the 4th quarter valued at $172,000. Institutional investors and hedge funds own 96.68% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on DYN. HC Wainwright restated a "buy" rating and set a $36.00 target price on shares of Dyne Therapeutics in a research report on Friday, May 3rd. Piper Sandler raised their target price on shares of Dyne Therapeutics from $27.00 to $29.00 and gave the company an "overweight" rating in a research note on Wednesday, March 6th. Morgan Stanley initiated coverage on shares of Dyne Therapeutics in a research report on Tuesday, April 30th. They set an "overweight" rating and a $40.00 price target for the company. Stifel Nicolaus raised their price objective on shares of Dyne Therapeutics from $35.00 to $41.00 and gave the company a "buy" rating in a research note on Wednesday, March 6th. Finally, Oppenheimer reaffirmed an "outperform" rating and set a $47.00 target price on shares of Dyne Therapeutics in a report on Monday, May 6th. One analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Dyne Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $37.75.

Insider Activity at Dyne Therapeutics

In related news, CEO Joshua T. Brumm sold 5,520 shares of the firm's stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $27.50, for a total transaction of $151,800.00. Following the sale, the chief executive officer now directly owns 563,471 shares in the company, valued at $15,495,452.50. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Dyne Therapeutics news, Director Jason P. Rhodes sold 119,360 shares of the company's stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $22.66, for a total transaction of $2,704,697.60. Following the completion of the transaction, the director now owns 6,512,104 shares of the company's stock, valued at approximately $147,564,276.64. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Joshua T. Brumm sold 5,520 shares of Dyne Therapeutics stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $27.50, for a total transaction of $151,800.00. Following the completion of the sale, the chief executive officer now owns 563,471 shares in the company, valued at $15,495,452.50. The disclosure for this sale can be found here. In the last three months, insiders sold 1,537,357 shares of company stock worth $36,442,642. 20.77% of the stock is owned by company insiders.

Dyne Therapeutics Price Performance

Shares of NASDAQ DYN traded down $1.07 during midday trading on Friday, reaching $27.68. 1,318,232 shares of the stock were exchanged, compared to its average volume of 793,466. Dyne Therapeutics, Inc. has a 12 month low of $6.40 and a 12 month high of $30.27. The business has a 50-day simple moving average of $26.58 and a two-hundred day simple moving average of $19.89. The company has a market capitalization of $2.42 billion, a price-to-earnings ratio of -6.97 and a beta of 1.00.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its earnings results on Thursday, May 2nd. The company reported ($0.81) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.81). Equities research analysts expect that Dyne Therapeutics, Inc. will post -3.1 earnings per share for the current fiscal year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.